Alation Acquires Numbers Station to Unlock a New Era of Agentic Workflows
REDWOOD CITY, Calif., May 20, 2025 (GLOBE NEWSWIRE) —
Alation Inc.
, the leader in enterprise data intelligence, today announced that it has acquired
Numbers Station AI
, a pioneer in building AI agents for data workflows. The combined capabilities of Alation and Numbers Station will accelerate the ability of data and engineering teams to quickly build and deploy a new class of AI-native analytics applications featuring agentic workflows that operate with enterprise-grade governance and context.
Organizations are demanding more effective ways to leverage their data for insights and real-time decisions, particularly in the era of AI. Despite its promise, scaled adoption in production use cases continues to be a challenge. For organizations to achieve what is truly possible with AI, they need systems that are trustworthy and deeply integrated with diverse enterprise data ecosystems.
Structured data—such as customer records, supply chain records, and financial transactions—represents an organization's most critical assets. AI agents struggle to understand and take action on that data due to incomplete semantics and data definitions, unclear governance policies, and missing context of the lineage and data quality of the underlying data sets. Without this foundation, agents risk producing inaccurate outputs and violating privacy and compliance requirements.
Together, Alation and Numbers Station are uniquely positioned to close this gap. By combining Numbers Station's agents with Alation's rich metadata foundation, customers will be able to build intelligent applications that reason over structured data, understand business context, and automate real-time decision-making—all while maintaining rigorous governance and compliance standards. This will unlock a new era of agentic workflows that can deliver tangible business outcomes at enterprise scale.
'Numbers Station has proven the impact AI agents can have in the enterprise when companies are able to trust this new way of working and brings an exceptional team that shares our obsession with empowering data users,' said Satyen Sangani, co-founder and CEO of Alation. 'Together, we're laying the foundation for the next decade of enterprise data intelligence—one where humans and agents collaborate seamlessly to turn data into action.'
'From the start, our vision has been to enable anyone to be a data app builder,' said Chris Aberger, co-founder and CEO of Numbers Station. 'By joining forces with Alation, we're pairing our AI-native foundation with the most trusted enterprise data intelligence platform. This unlocks a future where agents don't just find data—they do more with it.'
Numbers Station, AI & Solving The Structured Data Problem for Businesses
Founded out of Stanford's PhD lab for machine learning and AI, the Numbers Station team authored the first academic paper to demonstrate how large language models could be deployed to meet the complex, domain-specific needs of enterprise data leaders. Numbers Station's agents bring automation and natural language interaction to tasks like data analysis, visualization, and end-to-end action—helping data teams build AI-native applications faster with more confidence.
As part of the acquisition, the Numbers Station team will join Alation to drive continued innovation at the intersection of AI and data. All existing Numbers Station customers will be fully supported and will benefit from expanded resources and roadmap continuity under Alation's platform.
To learn more about the acquisition, read the blog, '
Alation Acquires Numbers Station: Enabling AI to Understand Structured Data at Scale
.'
About Alation
Alation is the data intelligence company. More than 600 global enterprises — including 40% of the Fortune 100 — rely on Alation to realize value from their data and AI initiatives. Customers such as Cisco, DocuSign, Nasdaq, Pfizer, and Samsung trust Alation's platform for
self-service analytics
,
cloud transformation
,
data governance
, and
AI-ready data
, fostering data-driven innovation at scale. Headquartered in Redwood City, California, Alation has been recognized five times by Inc. Magazine as one of the Best Workplaces. To learn more, visit
www.alation.com
.
Media Contact
Ashley Womack
Sr. Director, Corporate Marketing
650-504-2647
ashley.womack@alation.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Fresh blow for London as US buyers mount £5bn raid on stock market
Two major British companies are poised to join the exodus from the London stock market after American rivals made multibillion-pound takeover offers for each. On Monday, semiconductor company Alphawave recommended a $2.4bn (£1.8bn) sale to US chip giant Qualcomm while high-tech equipment maker Spectris urged shareholders to back a £4.4bn sale to private equity house Advent International. The deals would mean both companies would cease to be listed in London, dealing a fresh blow to the City just days after Wise, the British financial technology champion, announced it was moving its main listing to New York. Both takeovers will also see the American buyers pay substantially above the share prices that their British targets commanded beforehand, prompting suggestions they may have been undervalued by London investors. Qualcomm's offer is more than 90pc above Alphawave's share price before talks began in April and the Spectris bid is 84pc higher than its stock price on Friday. Charles Hall, head of research at Peel Hunt, said: 'The bids for Spectris and Alphawave show how undervalued UK listed companies are given premiums of 85pc and 96pc respectively.' 'It continues the constant theme of companies leaving the market, with 30 takeovers of scale and just one initial public offering on the London Stock Exchange in 2025.' 'Urgent action is required if we want a healthy UK equity market that supports our listed companies and encourages the next generation of companies to list.' Qualcomm said it was buying Alphawave to aid its expansion into data centres, which are becoming increasingly important in the race to develop artificial intelligence (AI) software. Alphawave is a specialist in technologies that 'drive faster, more reliable data transfer with higher performance and lower power consumption', a joint statement by the companies said. This means its products 'form a part of the core infrastructure enabling next-generation services in a wide array of high growth applications, including data centres, AI, data networking and data storage'. Silicon Valley giants such as OpenAI, Google and Amazon are racing to acquire more data centre capacity to help train their AI programmes. Tony Pialis, the president and chief executive of Alphawave, said: 'Together, we will unlock new opportunities for growth, drive innovation, and create a leading player in AI compute and connectivity solutions. 'For our shareholders, the Alphawave board is pleased that Qualcomm's offer provides an opportunity to realise compelling value for their shares.' Spectris, which is headquartered in London, makes various high tech instruments, including particle measuring systems used in the pharmaceutical industry. Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
40 minutes ago
- Yahoo
Tredence Wins Fourth Consecutive Databricks Retail and CPG Partner of the Year Award at Data + AI Summit
Trusted by 8 of the top 10 retailers and CPGs and recognized for driving last mile AI impact by modernizing data, industrializing GenAI, and scaling AI. SAN FRANCISCO, June 10, 2025 /PRNewswire/ -- Tredence, a global data science and AI solutions company, today announced that it has been named the Databricks Retail & CPG (RCG) Partner of the Year for the fourth consecutive year. Tredence was selected for their standout expertise in harnessing the Databricks Data Intelligence Platform and deep domain expertise to drive exceptional value for retail and CPG clients. Presented at the annual Databricks Data + AI Summit, the award celebrates Tredence's exceptional contributions to modernizing data and AI infrastructure, accelerating GenAI implementation, and scaling AI adoption across some of the world's largest retailers and consumer brands, collectively generating over $2T in global revenue. Over the past year, Tredence has demonstrated an unparalleled commitment to helping Retail and CPG enterprise organizations build data intelligence through its collaboration with Databricks, the Data and AI company. "Tredence is the AI expert driving the Data & AI strategy for 8 of the top 10 global retailers. Together with Databricks, we're helping industry leaders modernize their data foundations, enhance governance, and operationalize GenAI," said Morgan Seybert, President and Chief Business Officer of Retail at Tredence. "Backed by our unified retail data model, 150+ AI/ML accelerators, and 12+ GenAI agents, we're solving complex data science and data engineering challenges at scale." "In CPG, speed and precision drives growth. We help brands unlock growth by bridging the gap between insight and action—using Agentic AI, predictive forecasting and connected data to optimize every shelf, in every market," said Sagar Balan, Chief Business Officer of CPG at Tredence. "Our collaboration with Databricks is helping CPG leaders turn insights into immediate business impact. This is where data stops being passive and starts delivering value that compounds." In FY25, Tredence and Databricks helped leading retail and CPG enterprises drive business value across three core areas: Modernization that delivers: Unlocked $220M EBITA, $13M in labor savings, and a 10%+ improvement in forecast accuracy for a leading grocery chain in the U.S. Monetization through intelligent activation: Enabled $58M+ in retail media network revenue, reduced platform licensing costs by 30–50%, and achieved 3–5X acceleration in time-to-insight for marketing and CX teams for a major American retailer. Industrialization of AI and GenAI: Scaled enterprise-wide GenAI leading to 3X faster adoption, 30% productivity boost, 100% compliance for a leading CPG enterprise. "Tredence continues to push the boundaries of how data and AI unlock value for our joint clients in retail and CPG," said Matt Jackson, Vice President of Sales, Retail & Consumer Goods at Databricks. "Their focus on last-mile analytics impact, coupled with a powerful library of Brickbuilder Solutions, is helping RCGs move faster—from data to decision." Adding to this honor, Tredence was also awarded the Databricks Growth Partner of the Year for the Americas, reaffirming its position as the trusted Data & AI partner to leading enterprises across the region. About Tredence Tredence is a global data science and AI solutions provider focused on solving the last-mile problem in AI – the gap between insight creation and value realization. Tredence leverages deep domain expertise, data platforms and accelerators, and strategic partnerships to provide targeted, impactful solutions to its clients. The company has 3,500+ employees across San Francisco Bay Area, Chicago, London, Toronto, and Bengaluru, serving top brands in Retail, CPG, Hi-tech, Telecom, Healthcare, Travel, and Industrials. For more information, visit and follow us on LinkedIn. Photo: View original content: Sign in to access your portfolio
Yahoo
40 minutes ago
- Yahoo
RenaissThera Achieves Discovery Milestone in Its Oral Obesity Drug Program
BENGALURU, India, June 09, 2025 (GLOBE NEWSWIRE) -- RenaissThera Private Limited ('RenaissThera'), a Bengaluru-based biotechnology company, announced a major milestone in its obesity drug discovery program targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR). GIPR, an incretin receptor, is a validated target for peptide-based parenteral therapies where both stimulation and inhibition has shown efficacy in treating obesity and its co-morbidities. RenaissThera is developing novel, oral small molecules, both agonists and antagonists, as a more affordable and convenient alternative aiming to expand access for underserved populations in the global obesity market projected to reach USD 38 billion by 2032. Oral small molecules are more economical to manufacture and distribute than peptide-based obesity drugs. These molecules were designed and screened using proprietary AI and ML based platforms, followed by demonstrating in-vitro activity in cell lines and in-vivo activity to impact GIPR in mice to yield 'Hits'. RenaissThera now is advancing these Hits to the Lead optimization program to select candidates for pre-IND studies. RenaissThera is filing 'Composition of Matter' and utility patents for these oral novel small molecule GIPR modulators and continues to expand its innovation portfolio targeting GIP, GLP-1, and apelin receptors in obesity and diabetes. Its AI-powered Innovation Platform, integrating GenAI and machine learning tools, is accelerating the design and optimization of novel small molecules. 'We are grateful to our investors and collaborators for supporting us in reaching this milestone. Our team is focused on pushing candidates toward IND-readiness next year and we are in active discussions with potential pharma partners and investors interested in our obesity program,' said Meena, MD, CEO of RenaissThera. RenaissThera's progress was enabled through its collaboration with VedTechBio Research Private Limited which enabled access to its Agentic AI platform RxAgentAI and discovery expertise. 'We are very pleased with the outcomes of our collaboration with RenaissThera. This milestone further validates our platform and capabilities across key therapeutic areas including obesity, Type 2 diabetes, oncology, and inflammation,' said VedTechBio's Managing Director Sudhir Nagarajan. About RenaissThera RenaissThera is a Bengaluru-based biotech company developing affordable, AI-powered novel small-molecule therapies for high-unmet-need diseases like obesity and diabetes. Its goal is to innovate for underserved populations and expand global access to novel therapies. It leverages India's CRO ecosystem for early-stage R&D to deliver globally relevant innovation. For more information Please contact: Media: Lakshmi Ramakrishna lramakrishna@ Investor & Partnership: Ramkesh Meena bd@
